Merck Signs $2.13 Bln License Deal With SciBrunch Therapeutics For KRAS G12D Inhibitor
(RTTNews) - Merck & Co., Inc. (MRK), an American multinational pharmaceutical company, announced on Monday that it has entered into an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Merck signs up to $2.13B license deal with SciBrunch seekingalpha.com
